Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 4
2005 2
2006 4
2007 6
2008 4
2009 6
2010 9
2011 10
2012 5
2013 2
2014 3
2015 2
2016 3
2017 1
2018 1
2019 5
2020 3
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: ehehalt r. Inflamm Bowel Dis. 2023 Jul 31:izad138. doi: 10.1093/ibd/izad138. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37523666
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: ehehalt r. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Sturm A, et al. Among authors: ehehalt r. Z Gastroenterol. 2022 Mar;60(3):332-418. doi: 10.1055/a-1713-3941. Epub 2022 Mar 9. Z Gastroenterol. 2022. PMID: 35263784 German. No abstract available.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798037 Clinical Trial.
Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline.
Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Kucharzik T, et al. Z Gastroenterol. 2020 Dec;58(12):e241-e326. doi: 10.1055/a-1296-3444. Epub 2020 Dec 1. Z Gastroenterol. 2020. PMID: 33260237 German. No abstract available.
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R. Helwig U, et al. Among authors: ehehalt r. BMC Gastroenterol. 2020 Jul 8;20(1):211. doi: 10.1186/s12876-020-01332-w. BMC Gastroenterol. 2020. PMID: 32640990 Free PMC article.
[August 2019 - AWMF-Registriernummer: 021-009].
Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Kucharzik T, et al. Z Gastroenterol. 2019 Nov;57(11):e1. doi: 10.1055/a-1108-3778. Epub 2020 Feb 18. Z Gastroenterol. 2019. PMID: 32069500 German. No abstract available.
Interdisciplinary Aspects of Chronic Inflammatory Bowel Diseases.
Kähler G, Böcker U, Ehehalt R, Götz M, Hasselblatt P, Kreis ME, Kroesen AJ. Kähler G, et al. Among authors: ehehalt r. Visc Med. 2019 Dec;35(6):359-361. doi: 10.1159/000504102. Epub 2019 Oct 29. Visc Med. 2019. PMID: 31934584 Free PMC article. No abstract available.
72 results